 Patients with MR organic intrinsic valve disease, isolated no other valve disease, moderate or more severe regurgitant volume 30 mLbeat. A Clinical trial, randomized, placebo controlled, double-blind, without cross-over, of 1 year oral treatment with potent angiotensin-II receptor blockade using 32 mg Candesartan daily. The trial is preceded in all patients by an acute open-label study to determine tolerance and immediate response. The methods used to measure the end-points will be: a Doppler-Echocardiography for quantitation of the degree of MR measurement of regurgitant volume using a combination of three simultaneous methods quantitative Doppler, quantitative two-dimensional echocardiography, proximal flow convergence and b of left ventricular remodeling end-diastolic volume index measured by echocardiography and by electron beam computed tomography. This single center study seeks to enroll a total of 90 patients. The analysis will be based on intention to treat and compare the regurgitant volume and left ventricular end-diastolic volume index measured after one year of treatment with the active drug or placebo. The results of the trial should provide strong evidence regarding medical treatment of patients with organic MR. 